Pfizer stock falls 1.14 percent as pipeline data sharpen debate

Published on 10/04/2026 at 11:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer stock was last at USD 27.80 on October 2, 2026, down 1.14 percent. Q2 revenue reached USD 15.03 billion as pipeline data met key endpoints.

Flatlay-Arrangement mit Zertifikat, ISIN-Karte und Pillenblistern, Symbolbild für Pfizer Inc — Flatlay mit Aktienzertifikat, ISIN-Karte und Tablettenblistern symbolisiert eine Investition in Pfizer Inc., ISIN US7170811035, Illustration mit AI erstellt.

Pfizer stock (ISIN US7170811035) was last at USD 27.80 on the NYSE on October 2, 2026 at 4:01 p.m. ET, down 1.14 percent from USD 28.12. The latest pipeline updates included positive Phase 3 vitiligo data for LITFULO and Phase 2 success for tilrekimig, according to MarketBeat on October 2, 2026.

Pipeline data meet a valuation test

The clinical updates matter because Pfizer is rebuilding growth outside its COVID portfolio. MarketBeat said LITFULO improved facial and total-body repigmentation in the TRANQUILLO and TRANQUILLO 2 Phase 3 trials, while tilrekimig met its primary endpoint in atopic dermatitis.

The share price remains below its October 2, 2026 52-week high of USD 29.21 and above the low of USD 23.62. Trading volume reached 34,914,894 shares, while market capitalization stood at USD 158.4 billion on the same date.

Guidance rises, but COVID sales shrink

Pfizer's second-quarter 2026 revenue was USD 15.03 billion, and adjusted EPS was USD 0.77, according to Fortune. Revenue increased 1 percent operationally from the prior year, while the company raised the midpoint of its full-year revenue guidance by USD 500 million.

The updated 2026 revenue range is USD 60.5 billion-USD 62.5 billion, versus USD 59.5 billion-USD 60.5 billion previously. Pfizer reaffirmed adjusted diluted EPS guidance of USD 2.80-USD 3.00, even after a USD 0.10 impact from an acquired in-process research and development charge.

Analysts see limited upside

MarketBeat reports a Hold consensus from 21 analysts and an average price target of USD 28.39. That target lies 2.12 percent above the October 2 reference price of USD 27.80.

Jefferies raised its Pfizer price target from USD 34 to USD 35 while retaining a Buy rating on October 1, 2026, according to finanzen.net. The new target lies 25.9 percent above the NYSE price, leaving the pipeline's execution and Pfizer's patent-loss exposure central to the stock case.

Pfizer stock awaits November results

Pfizer stock was last at USD 27.80 on the NYSE on October 2, 2026 at 4:01 p.m. ET. The company is scheduled to publish its third-quarter 2026 performance report on November 3, 2026.